What Brightest Bio does

Brightest Bio (legal entity Auragent Bioscience, LLC) is a US life-sciences tools company headquartered in Overland, Missouri, that develops and sells ultrasensitive immunoassay kits, a dedicated plate reader, and analysis software for academic and biomedical research use. The company's product portfolio is built on a proprietary Plasmonic Fluor nanoconstruct technology reported to be over 10,000 times brighter than conventional molecular fluorophores, which translates into 50-1000x improvements in assay sensitivity compared to standard ELISA while preserving an ELISA-like workflow on standard 96-well plates. The core platforms include PFLISA-PLEX (pre-configured multiplex panels up to 12 analytes per well), PFLISA-FLEX (customizable singleplex homebrew assays), PFluorospot (single-cell secretion), and a Serology Kit capable of detecting up to 20 targets per well using sub-microliter sample volumes.

The company operates a direct-to-researcher go-to-market model through its e-commerce website, with products sold strictly for research use only and not for clinical, therapeutic, or diagnostic applications. Revenue is generated through four streams: consumable kit and reagent sales (one-time purchases), hardware sales of the Discovery Reader instrument, software licenses for data acquisition and analysis, and ancillary professional services. Pricing is not publicly disclosed but is positioned as affordable for the individual researcher rather than large core facilities, with invoices due net 30 and shipments made Ex Works from the Missouri facility. Distribution is domestic only, with no disclosed channel partners, distributors, or international shipping arrangements.

Brightest Bio is a private, founder-led LLC with 11-50 employees and no disclosed institutional investors or venture funding in the available source material. The company was selected into the BioTools Innovator program in August 2025, indicating engagement with the life-sciences tools accelerator ecosystem. Customer segments are horizontal across academic researchers and biomedical scientists, with no named enterprise accounts, published customer logos, or disclosed revenue figures in the source data.

Name

Brightest Bio

Legal name

Auragent Bioscience, LLC

Website

https://brightestbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Brightest Bio (Auragent Bioscience, LLC) develops and sells ultrasensitive multiplex immunoassay kits, a plate reader, and analysis software based on proprietary Plasmonic Fluor technology, sold directly to academic and biomedical researchers in the United States for research use only.

Ownership category

akta.pro rank

Product category

Immunoassay Research Kits

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Immunoassay kits
• Multiplex immunoassays
• Biomarker detection reagents
• Single-cell analysis kits
• Serology assays

Headquarters

HQ city

Overland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Kits and Reagents): Sale of PFLISA kits (pre-configured multiplex panels), PFLISA-FLEX plates (for custom assay development), PFluorospot kits, and serology assay kits. Products are sold for research use only.
2. Hardware Sales (Discovery Reader): Sale of the Discovery Reader instrument for reading and analyzing assay plates. Priced for individual researchers.
3. Software Licenses: Software for data acquisition and analysis, licensed for use with the company's assay platforms.
4. Professional Services: Service parts and support services related to product installation and maintenance.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Brightest Bio develops and sells ultrasensitive immunoassay kits, reagents, instruments, and software built on proprietary Plasmonic Fluor technology for biomedical research. Its product family includes the PFLISA multiplex and singleplex immunoassay platforms, PFluorospot single-cell secretion assays, and Serology kits, complemented by the Discovery Reader plate instrument and data analysis software. All products are sold for research use only through the company's direct e-commerce website, priced for individual researchers and academic labs.

Product overview

Brightest Bio offers a unified platform of ultrahigh sensitivity immunoassay products centered on its proprietary Plasmonic Fluor technology. The core product family includes PFLISA-PLEX (pre-configured multiplexed immunoassay kits measuring up to 12 analytes per well), PFLISA-FLEX (customizable singleplex homebrew assay platform), PFluorospot (single-cell secretion assay), and Serology Kit (antibody detection assay). These assays are complemented by the Discovery Reader instrument and Software for data analysis. All products share the common technology platform of ultrabright Plasmonic Fluor, enabling 50-1000X higher sensitivity than conventional ELISA while maintaining an ELISA-like workflow.

Differentiator

Problem solved

Functional benefit

Brands

• PFLISA: Ultrasensitive multiplexed immunoassay platform technology enabling >100X higher sensitivity than ELISA with measures up to 12 analytes per well.
• PFluorospot
• Serology

Products and services

• PFLISA-PLEX Ultrasensitive multiplexed immunoassay kit using ultrabright Plasmonic Fluor technology, providing greater than 100X higher sensitivity than ELISA and measuring up to 12 analytes per well on a 96-well plate for biomedical researchers.
• PFLISA-FLEX Ultrasensitive singleplex homebrew assay platform supporting rapid customization of tailored PFLISA assays with user-defined antibodies and reagents, offering 50–1,000X higher sensitivity than ELISA and 4–6 orders of magnitude dynamic range, with no capture antibody labeling required.
• PFLISA Kits Ready-to-use multiplex immunoassay panel kits for the PFLISA-PLEX platform, including Human Inflammation (2-12 Plex), Human Neurology (2-3 Plex), Human Barrier Integrity, and Human Oncology panels sold to biomedical researchers.
• PFluorospot Improved single-cell secretion assay using ultrabright Plasmonic Fluor technology, offering fewer steps and easier workflow than ELISPOT with no artifacts from membrane or color development, intended for biomedical researchers.
• Serology Kit Ultrahigh sensitivity serology assay detecting IgG subclasses and total IgG on one plate, with ability to detect antibodies against up to 20 different target antigens using less than 0.5 µL of undiluted sample.
• Discovery Reader Automated plate reader instrument with intuitive interface, fast read times (less than 13 minutes), zero maintenance design, and built-in automated data analysis for use with Brightest Bio's assay platforms.
• Discovery Software Data analysis software providing user-friendly workflow management, efficient analysis patterns, fast results transformation, and Agnostic RESTful APIs for customizing acquisition and analysis pipelines used with Brightest Bio's assay platforms.

Quantifiable outcome

• Over 10,000x brighter than molecular fluorophores
• +7 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Bio-Rad Laboratories: Bio-Rad's Bio-Plex multiplex immunoassay system is a long-standing competitor in research multiplex immunoassays. As a broad life-science tools incumbent, Bio-Rad has substantially larger distribution, manufacturing, and installed-base advantages.
• MilliporeSigma (Life Science business of Merck KGaA): MilliporeSigma is a global leader in research ELISA kits, antibodies, and immunoassay reagents. Its breadth of catalog offerings and global distribution represent both competition and a channel benchmark Brightest Bio lacks.
• Revvity (formerly PerkinElmer Life Sciences): Revvity offers immunoassay kits, reagents, and instruments (including AlphaLISA and HTRF technologies acquired via Cisbio) that compete in the same biomarker research workflows Brightest Bio targets with PFLISA.
• Thermo Fisher Scientific: Thermo Fisher's life-science tools portfolio (including ELISA kits, antibodies, and ProcartaPlex multiplex assays) competes broadly in the same immunoassay research market, with vastly larger sales reach and catalog breadth.

Direct peers

• Olink Holding: Olink's Proximity Extension Assay (PEA) technology enables high-multiplex ultrasensitive protein biomarker detection, directly competing with PFLISA in proteomics research and translational biomarker discovery workflows.
• Quanterix: Quanterix's Simoa platform is a single-molecule ultrasensitive immunoassay that competes directly with Brightest Bio's plasmonic-fluor approach. Both target low-abundance biomarker detection in research and translational applications.
• Meso Scale Diagnostics: MSD's MULTI-ARRAY and V-PLEX platforms are the closest direct competitor to PFLISA, offering ultrasensitive multiplex electrochemiluminescence immunoassays for biomarker research. Targets the same academic and biopharma customer base with comparable sensitivity claims.
• Abcam: Abcam provides research-use-only antibodies and immunoassay kits serving academic and translational researchers globally. Its DTC e-commerce motion and researcher focus closely parallel Brightest Bio's go-to-market, though at much larger scale post-Danaher acquisition.
• Luminex (DiaSorin): Luminex's xMAP bead-based multiplex platform serves the same research and clinical research customer base for biomarker multiplexing. Now owned by DiaSorin, Luminex offers both RUO and clinical IVD immunoassay content.

Emerging players

• Singulex (Erenna) — now part of EMD Millipore: Singulex's Erenna single-molecule counting immunoassay platform pioneered ultrasensitive detection with similar sensitivity claims to PFLISA. Now distributed via EMD Millipore, it competes for the same low-abundance biomarker research opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/brightest-bio

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brightest Bio